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Posttransplant Donor-Specific T -Lymphocytotoxic Antibody in Liver 
Transplant Patients With a Positive Crossmatch 
M. Kobayashi, A. Yaglhashi, R. Manez, S. Takaya, K. Noguchi, A. Konno, Y. KitB, Y. Yoshida, 
K. Terasawa, T.E. Starzl, and Y. Iwaki 
PREFORMED donor-specific T-Iymphocytotoxic anti-body (DSTAb) has an adverse effect on patients with 
orthotopic liver transplantation (OLTx), yet some liver 
allografts were tolerated with cytotoxic antibody-mediated 
rejection. I - J To study such an antibody effect further, we 
monitored posttransplant DST Ab for patients who re-
ceived OL Tx across a positive T -lymphocyte cross-
match. 
MATERIALS AND METHODS 
This study consisted of 40 patients who received primary liver 
transp\alltation across a positive T-Iymphocyte crossmatch at the 
Univel"Sity of Pittsburgh Medical Center. between November 
1989 and December 1991. Initial immunosuppression comprised 
cyclosporine A (4 cases) or FK 506 (36 cases), in combination with 
a low4ose (17 cases) or high-dose steroid (23 cases). The protocol 
for COIIIbined steroid therapy was the foUowing: low dose. 20 mg/d 
of medlytprednisolone given on the day of transplantation and 
contiDued during the first 2 weeks posttranspiant, then decreased 
to 10 nw'd. In high-dose steroid therapy. methylprednisolone was 
started at 200 mg/d in the operating room. and decreased daily by 
40 mg:antil reaching 20 mg/d. All patients were monitored for their 
DST Ab level in serum samples coUected every week for 2 months 
fo~ OLTx. The lymphocyte cytotoxicity test was performed 
with didIiothreitol (Om-treated sera according to the National 
IIJStitules of Health standard procedure. and the reactivity of 
DSTAb was decided by the end point of cytotoxic titer using 
2-fokl diluted serum up to 1:32. Actuarial graft survival was 
compuled by the life-table method. and patient death. as weU as 
graft mmoval. was considered graft failure, regardless of the 
reason. 
RESlLTS 
ACCORting to posttransplant DST Ab titer. 40 patients were 
divided into two groups: group 1 consisted of 25 patients 
who became negative in the first 2 months posttranspiant, 
and group 2 comprised 15 patients who had an increased or 
stable liter over a 2-month period fonowing OLTx. Figure 
1 illUSlrates the graft outcomes of these two groups. The 
survival rate of group 2 dropped markedly during the first 
3 weeCsposttransplant, with graft survival rates of 53.3%, 
40.0%. and 33.3% at 1,2, and 3 months, respectively. On 
the other hand, the graft survival rates of Group 1 were 
96.0%.88.0%, and 88.0% at 1,2, and 3 months, respec-
tively. 'Wbich were higher than those of Group 2. 
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Fig 1. Effect of posttransplant donor-specific T-Iymphocytotoxic 
antibody (DSTAb) on liver graft outcome. 
DISCUSSION 
Although a detrimental effect was observed for patients 
who received orthotopic liver transplantation across a 
positive crossmatch, our earlier study revealed that this 
effect was minimal compared to that observed in kidney 
transplant recipients. I- 3 As a result, the liver has been 
considered invulnerable from an antibody-mediated in-
jury. However. this study clearly indicated that if a patient 
possessed a persistent DST Ab during the early posttrans-
plant period, the transplant outcome was significantly low. 
In fact. a 3-month survival rate as low as 33% was 
observed in such recipients. These data suggest that the 
transplanted liver could also be a target of the antibody 
injury, and the presence of posttransplant donor-specific 
antibody seems to be more substantial than the pretrans-
plant antibody. If this were the case. efforts should be 
made to reduce the posttransplant antibody titer for pa-
tients with a positive crossmatch. Although an extended 
study is required, our preliminary data reveal that a high 
dose of steroid administration is effective in reducing 
posttransplant DST Ab in patients with pretransplant anti-
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body,4 which would relieve the transplanted liver from an 
antibody-mediated injury. 
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